Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019693 (HIV)
 170,526 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Oxandrin and Anadrol-50 are both oral anabolic steroids approved by the Food and Drug Administration (FDA), and they are competing for market share in the world of HIV treatments. Both are described as "open label" drugs and as such, are prescribed to reverse wasting and metabolic complications associated with HIV. Anadrol-50 is among the most potent steroids ever developed for building muscle, and study participants gained an average of 14.5 pounds for each 100 pounds of weight. Early studies indicate minimal side effects with liver toxicity, but that is not a certainty since oral anabolics are known for liver toxicity. Many studies have documented Oxandrin's safety and effectiveness in treating HIV wasting. It is metabolized in the kidney and acts without the masculinizing side effects associated with other steroids, such as Anadrol-50. One study showed an average weight gain of 24 pounds following 8 months of treatment. Oxandrin is the best choice for those at the earliest stages of AIDS wasting syndrome. However, when a more aggressive treatment is necessary, Anadrol-50 is stronger, less expensive, and more effective, but liver function must be monitored closely.
 ...
PMID:Comparing Oxandrin and Anadrol-50. 1136 32

Promising new developments involving four anti-HIV agents are described. HE2000, a new treatment for end-stage disease, may interrupt HIV's entry into cells, thus preventing damage. Norvir-SGC, a new gel-capsule form, available June or July 1999, should aid in eliminating the foul taste of the drug, and lessen the chance of diarrhea. New studies of Anadrol-50, a drug promoting lean muscle growth, suggest it is not metabolized by the same liver pathway as most drugs used to treat HIV. Therefore, it probably will not interact with drug "cocktails" or highly active antiretroviral therapy regimens. Research indicates that hydroxychloroquine, a drug for managing rheumatic illness and lupus, may disrupt HIV's attachment to key immune cells including macrophages. However, clinical trials are not being done with this inexpensive drug in favor of using more expensive drugs.
 ...
PMID:Drug watch. 1136 96